Esaprazole, also known as hexaprazole, was developed in the 1980s as a drug for the treatment of gastric and duodenal ulcers. Esaprazole exerts a dose-dependent cytoprotective effect on the gastric mucosa in man. It was shown to have a dose-dependent antisecretory activity, which was particularly evident on secretion volume and acid output. Esaprazole completed phase II clinical trials with only a few minor side effects being reported, but was shown to be less effective than Cimetidine and Ranitidine at healing ulcers. Esaprazole is a weak sigma opioid receptor and muscarinic acetylcholine receptors M3 and M5 ligand. Esaprazole analogs with many compounds showing neuroprotective properties.

Nisbuterol, a nicotinic acid ester, is a bronchodilator.

Salantel was used in veterinary as an anthelmintic agent. Information about the current use of this compound is not available.

Niludipine (Bay-a-7168) is a potent calcium antagonistic coronary vasodilator with less cardiodepressant effect than nifedipine. Niludipine is a safe antianginal Ca2+-antagonist with broad effectiveness for various types of angina pectoris. Niludipine is clinically useful as coronary vasodilator and hypotensive agent.

Salmisteine was studied as an antipyretic and mucolytic agent. Information about the current use of this compound is not available.

Etisulergine (CQ 32-084) is an ergoline derivative. Etisulergine stimulates both dopamine D1- and D2-receptors, antagonizes alpha-adrenergic and serotonin 5-HT2 receptors. Etisulergine demonstrated antiparkinsonian activity in patients.

Etofenprox is a synthetic pyrethroid insecticide compound used in agricultural production. Etofenprox acts on the nervous system of insects by disrupting their neuron sodium channels. Etofenprox is a contact-kill adulticide used to control a wide variety of insects including weevils, beetles, aphids, moths, whiteflies, thrips, borers, fleas and mosquitoes. Etofenprox is well tolerated by mammals, including cats, and is environmentally friendly.

Evandamine is an anti-inflammatory agent.

Nomelidine (norzimelidine), the active N-demethylated metabolite of zimelidine, is a potent and specific inhibitor of [14C]5-HT uptake in synaptosome rich homogenates of rat hypothalamus. Nomelidine inhibits the uptake of 5-HT more potently than the parent compound. Zimelidine (ZIM) and its main active metabolite norzimelidine (NZIM) have been shown to preferentially inhibit 5-hydroxytryptamine (5-HT) neuronal uptake both in vitro and in vivo while having much less effect on noradrenaline (NA) uptake.

Nolomirole (CHF1035) is an orally active, selective dopamine agonist, primarily activating DA2- and alpha2 receptors, thereby inhibiting norepinephrine release, which may be beneficial in heart failure. Nolomirole is able to attenuate the heart failure signs in the monocrotaline-induced congestive heart failure. CHF1035 is a mixture of two enantiomers, CHF1800 (+) and CHF1810 (-). CHF1035 and its metabolite CHF1024 significantly decreased the IOP in rabbits, and are potential novel IOP lowering agents. Especially, CHF1035 produced a substantial decrease in IOP for a prolonged period of time, and thus may prove useful in glaucoma therapy. Nolomirole is a pre-synaptic stimulator of DA2-dopaminergic and α2-adrenergic receptors in peripheral sympathetic nerve endings. These receptors act as a negative feedback mechanism, inhibiting norepinephrine secretion. In early phase clinical studies lasting 1–3 months, nolomirole reduced peripheral systemic resistance and 24 hour blood pressure and increased cardiac output. In a study of 29 patients with heart failure, followed for 10 days, a reduction in plasma norepinephrine was demonstrated. In spite of the fact that Nolomirole was in clinical trials for the treatment of heart failure, its development was discontinued.